United States Ovarian Cancer Diagnostics Market Witnesses Notable Growth, Expected to Propel at a CAGR of 5.79% Through 2029 - Advancements in Imaging and Genetic Testing as Major Growth Drivers
10 juil. 2024 04h06 HE
|
Research and Markets
Dublin, July 10, 2024 (GLOBE NEWSWIRE) -- The "United States Ovarian Cancer Diagnostics Market, By Region, Competition, Forecast and & Opportunities, 2019-2029F" report has been added to ...
Ovarian Cancer Pipeline Drugs Analysis, 2024: Insights on 180+ Companies and 200+ Pipeline Drugs, Including Atezolizumab (Genentech), Tisotuma Vedotin (Genmab), and SON-1010 (Sonnet Biotherapeutics)
10 juin 2024 10h11 HE
|
Research and Markets
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Ovarian Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Polycystic Ovary Syndrome (PCOS) Treatment Global Strategic Research Report 2024-2030: North America and Europe Dominates, Asia-Pacific to Exhibit Fastest Growth
17 mai 2024 09h25 HE
|
Research and Markets
Dublin, May 17, 2024 (GLOBE NEWSWIRE) -- The "Polycystic Ovary Syndrome (PCOS) Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global...
Polycystic Ovarian Syndrome (PCOS) Competitive Landscape Report 2024: Out of 18 Drugs in the Pipeline for PCOS, Only 3 have Reached the Phase III Stage of Development
09 avr. 2024 10h50 HE
|
Research and Markets
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Polycystic Ovarian Syndrome (PCOS) - Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This report presents a...
Ovarian Cancer Opportunity Assessment Report 2024: A Blockbuster Market that is Expected to Grow from $3.3 Billion in 2022 to $4.1 Billion in 2032 with ImmunoGen, AstraZeneca, Merck, & GSK Dominating
09 avr. 2024 07h02 HE
|
Research and Markets
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.Ovarian Cancer is one of the most...
[Latest] Global Hereditary Cancer Testing Market Size/Share Worth USD 12.1 Billion by 2033 at a 7.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
02 avr. 2024 14h00 HE
|
Custom Market Insights
Austin, TX, USA, April 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hereditary Cancer Testing Market Size, Trends and Insights By Disease Type...
[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 mars 2024 14h30 HE
|
Custom Market Insights
Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib,...
Polycystic Ovary Syndrome (PCOS) Treatment Market Forecast: Projected Substantial Growth by 2031
25 janv. 2024 14h07 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Polycystic Ovary Syndrome (PCOS) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology,...
Germ Cell Tumor Market revenue to hit USD 122 Billion by 2035, says Research Nester
21 nov. 2023 06h30 HE
|
Research Nester
New York, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The global germ cell tumor market size is projected to grow at a CAGR of over 12% from 2024-2036. The market is expected to garner a revenue of USD 122...
Theratechnologies annonce l’administration du sudocétaxel zendusortide à la première patiente de l’essai clinique mis à jour sur le traitement du cancer de l’ovaire avancé
12 oct. 2023 07h30 HE
|
Theratechnologies
Un jalon pour le principal conjugué peptide-médicament de la Société après l’acceptation par la FDA, le 2 juin 2023, de la modification du protocole de l’étude de phase 1. MONTRÉAL, 12 oct....